SERPATE
Clinical safety rating
cautionComprehensive clinical and safety monograph for SERPATE (SERPATE).
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, enhancing serotonergic neurotransmission.
| Metabolism | Hepatic primarily via CYP2C19, CYP2D6, CYP3A4, and CYP2C9; active metabolite desmethylsertraline. |
| Excretion | Primarily renal excretion of unchanged drug (60-80%); biliary/fecal elimination accounts for 15-20%. |
| Half-life | Terminal half-life of 12-15 hours (range 10-18h) in adults; prolonged in renal impairment (up to 30h in severe cases). |
| Protein binding | 95-98% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5-0.7 L/kg (suggests moderate tissue penetration; primarily extracellular distribution). |
| Bioavailability | Oral: 70-80% (first-pass metabolism 20-30%; food reduces absorption by 10-15%). |
| Onset of Action | Oral: 30-60 minutes; IV: 2-5 minutes. |
| Duration of Action | Oral: 6-12 hours; IV: 4-6 hours. Duration extended in hepatic or renal impairment. |
| Molecular Weight | 325.23 |
50 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | No dosage adjustment required for GFR ≥30 mL/min; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 25 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not approved for pediatric use. |
| Geriatric use | No dosage adjustment required; monitor renal function. |
| 1st trimester | Avoid due to teratogenic risk; may cause fetal malformations. |
| 2nd trimester | Avoid; risk of fetal toxicity outweighs benefits. |
| 3rd trimester | Avoid; potential for neonatal adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for SERPATE (SERPATE).
| Placental transfer | Crosses placenta; documented in animal and human studies. |
| Breastfeeding | Excreted in breast milk; not recommended due to potential for serious adverse effects in nursing infants. |
| Lactation Rating | L5 |
| Teratogenic Risk | SERPATE is contraindicated in pregnancy. First trimester exposure carries risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. For all trimesters, increased risk of spontaneous abortion and stillbirth has been reported. |
| Fetal Monitoring | In pregnant women exposed to SERPATE, monitor fetal growth via ultrasound every 4 weeks. Perform serial amniotic fluid volume assessments. Evaluate for fetal malformations with detailed anatomy scan at 18–20 weeks. Monitor mother for signs of preeclampsia and hepatic dysfunction. After delivery, monitor neonate for withdrawal symptoms and respiratory depression. |
| Fertility Effects | SERPATE may impair female fertility based on animal studies showing disruption of estrous cycles and reduced ovarian follicle counts. In males, decreased sperm motility and morphology have been observed. Reversibility is unknown. Advise patients planning pregnancy of potential fertility risks. |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
| Serious Effects |
Hypersensitivity to serpateSevere hepatic impairmentConcomitant use with MAO inhibitors
| Precautions | Suicidality risk in pediatric/young adult patients, Serotonin syndrome risk with concomitant serotonergic drugs, Bleeding risk with anticoagulants/antiplatelets, Activation of mania/hypomania, Seizure risk in patients with epilepsy, Angle-closure glaucoma risk, Hyponatremia risk in elderly/dehydrated patients, Discontinuation syndrome with abrupt cessation |
| Food/Dietary | Grapefruit and grapefruit juice may increase sertraline levels; avoid consumption., Alcohol: Avoid or limit intake to prevent worsening of side effects and reduced drug efficacy., St. John's Wort: Concomitant use increases risk of serotonin syndrome; avoid. |
| Clinical Pearls | SERPATE is a brand name for sertraline, a selective serotonin reuptake inhibitor (SSRI). Initiate at 25-50 mg daily, titrate up to 200 mg maximum. Monitor for serotonin syndrome, especially with other serotonergic drugs. Abrupt discontinuation may cause withdrawal symptoms; taper gradually. Use with caution in bipolar disorder due to risk of manic switching. Adjusted dosing may be needed in hepatic impairment; no adjustment for renal impairment. May increase risk of bleeding, especially with NSAIDs or anticoagulants. Monitor for hyponatremia in elderly or volume-depleted patients. |
| Patient Advice | Take sertraline exactly as prescribed, usually once daily with or without food. · It may take 2-4 weeks to feel full benefit; do not stop abruptly without consulting your doctor. · Common side effects include nausea, diarrhea, dry mouth, dizziness, and trouble sleeping; these often improve over time. · Contact your doctor immediately if you experience signs of serotonin syndrome (e.g., agitation, hallucinations, fever, fast heart rate, muscle stiffness, twitching, coordination problems) or bleeding (e.g., unusual bruising, nosebleeds). · Avoid alcohol, as it can worsen side effects and reduce drug effectiveness. · Inform all healthcare providers that you are taking sertraline, especially before surgery or any procedure. · If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks and benefits with your doctor. · Do not take with MAO inhibitors (e.g., linezolid, methylene blue) or within 14 days of stopping them. · Store at room temperature away from moisture and heat. |
Loading safety data…